Pirfenidone(AMR69) is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Phase 3.

Pirlindole is a novel potent inhibitor of Enteroviruse that targets Viral Protein 2C, inhibits EV-B and EV-D through the inhibition of genome replication (CV-B3 EC50=9.91 uM). .

PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain binding with IC50 of 30 uM, Kd of 43.2 uM.

Pivmecillinam(Amdinocillin pivoxil) is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic.

Pizuglanstat is a potent, selective prostaglandin D synthase inhibitor..

PJ-68 is a potent, selective inhibitor of arginine methyltransferase PRMT5 with IC50 of 517 nM, shows no inhibitory activity against type I PRMT family members ( (PRMT1, 3, 4, 6, and 8).

PK4C9 (Homocarbonyltopsentin) is a small-molecule stem-loop RNA structure TSL2-binding compound (EC50=16.1 uM) that increases SMN2 exon 7 (E7) splicing and rescues downstream molecular alterations in SMA cells.

PK-7088 is a small molecule mutant p53 Y220C reactivator, promotes correct folding of Y220 mutant p53 and induces expression of p53 targets p21 and the Noxa, triggers nuclear export of the pro-apoptotic Bax protein to mitochondria..

PKC-412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity.

PKC-IN-1 is a poent PKC beta II inhibitor with Ki of 14.9 nM, extracted from patent WO 2008096260 A1 as compound example H6..

PKC-IN-7 is a potent, selective, reversible, ATP-competitive PKCα/β inhibitor with IC50 of 4.7/3.3 nM.

PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively; also potent to PI3Kα mutants E545K and H1047R.

PL265 (PL-265) is a dual enkephalinase inhibitor, alleviate corneal pain and inflammation in vivo..

Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].

Plecanatide acetate is a guanylate cyclase-C (GC-C) receptor agonist, binds and activates GC-C receptor, with an EC50 of 190 nM in T84 cells. Plecanatide acetate shows an-inflammatory activity in models of murine colitis.

PLK1-IN-14f is a potent PLK1 inhibitor, exhibits potent activity against a panel cancer cell lines with GI50 values ranging from 0.30 to 0.60 uM.

Plocabulin (PM060184) is a novel tubulin-binding agent binding to αβ-tubulin dimer with nanomolar affinity, inhibits a panel of 23 tumor cell lines with GI50 of 20 pM-5 nM.

PM-43I is a selective inhibitor of STAT5/6 Src Homology 2 (SH2) domain, binds recombinant STAT6 and STAT5B (IC50=1.8 and 3.8 uM) with much lower affinity for STAT3 (IC50=29.9 uM).

PMX53 (Ac-Phe-cyclo(Orn-Pro-D-Cha-Trp-Arg)) is a potent C5a receptor (CD88) antagonist with IC50 of 20 nM, also is an agonist for Mas-related gene 2 (MrgX2) in human mast cells; PMX-53 (10 nM) inhibited C5a-induced Ca(2+) mobilization in HMC-1 cells, but at higher concentrations (>30 nM) it caused degranulation in LAD2 mast cells, CD34(+) cell-derived mast cells, and RBL-2H3 cells stably expressing MrgX2; inhibits zymosan-, carrageenan-, LPS- and antigen-induced hypernociception in rats.

PNPLA4-IN-1 is a potent, selective, and irreversible PNPLA4 inhibitor with IC50 of 1.8 uM (separated membrane proteome fraction), shows in-cell inhibition of PNPLA4 with IC50 of 11.7 uM..

PNR-7-02 is a specific inhibitor of human DNA Polymerase η (hPol η) with IC50 of 8 uM, exhibits 5-10-fold specificity for hPol η over other replicative Pols.

PNRI-299 is an inhibitor of activator protein-1 (AP-1) transcription (IC(50) of 20 microM) without affecting NF-kappaB transcription (up to 200 microM) or thioredoxin (up to 200 microM).